Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.

Sikic D, Keck B, Wach S, Taubert H, Wullich B, Goebell PJ, Kahlmeyer A, Olbert P, Isfort P, Nimphius W, Hartmann A, Giedl J; Bridge Consortium.

PLoS One. 2017 Jun 20;12(6):e0179602. doi: 10.1371/journal.pone.0179602. eCollection 2017.

2.

Cellular Hierarchy as a Determinant of Tumor Sensitivity to Chemotherapy.

Rodriguez-Brenes IA, Kurtova AV, Lin C, Lee YC, Xiao J, Mims M, Chan KS, Wodarz D.

Cancer Res. 2017 May 1;77(9):2231-2241. doi: 10.1158/0008-5472.CAN-16-2434. Epub 2017 Feb 24.

PMID:
28235762
3.

Urothelial generation and regeneration in development, injury, and cancer.

Wang C, Ross WT, Mysorekar IU.

Dev Dyn. 2017 Apr;246(4):336-343. doi: 10.1002/dvdy.24487. Epub 2017 Mar 2. Review.

PMID:
28109014
4.

Stage- and subunit-specific functions of polycomb repressive complex 2 in bladder urothelial formation and regeneration.

Guo C, Balsara ZR, Hill WG, Li X.

Development. 2017 Feb 1;144(3):400-408. doi: 10.1242/dev.143958. Epub 2017 Jan 3.

PMID:
28049658
5.

Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers.

Skowron KB, Pitroda SP, Namm JP, Balogun O, Beckett MA, Zenner ML, Fayanju O, Huang X, Fernandez C, Zheng W, Qiao G, Chin R, Kron SJ, Khodarev NN, Posner MC, Steinberg GD, Weichselbaum RR.

Sci Rep. 2016 Oct 24;6:35854. doi: 10.1038/srep35854.

6.

Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.

Ferreira-Teixeira M, Paiva-Oliveira D, Parada B, Alves V, Sousa V, Chijioke O, Münz C, Reis F, Rodrigues-Santos P, Gomes C.

BMC Med. 2016 Oct 21;14(1):163.

7.

Role of angiogenesis in urothelial bladder carcinoma.

Fus ŁP, Górnicka B.

Cent European J Urol. 2016;69(3):258-263. Epub 2016 Jul 13. Review.

8.

Claudin-low bladder tumors are immune infiltrated and actively immune suppressed.

Kardos J, Chai S, Mose LE, Selitsky SR, Krishnan B, Saito R, Iglesia MD, Milowsky MI, Parker JS, Kim WY, Vincent BG.

JCI Insight. 2016 Mar 17;1(3):e85902.

9.

Positive association of collagen type I with non-muscle invasive bladder cancer progression.

Brooks M, Mo Q, Krasnow R, Ho PL, Lee YC, Xiao J, Kurtova A, Lerner S, Godoy G, Jian W, Castro P, Chen F, Rowley D, Ittmann M, Chan KS.

Oncotarget. 2016 Dec 13;7(50):82609-82619. doi: 10.18632/oncotarget.12089.

10.

Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting.

Lerner SP, McConkey DJ, Hoadley KA, Chan KS, Kim WY, Radvanyi F, Höglund M, Real FX.

Bladder Cancer. 2016 Jan 7;2(1):37-47.

11.

KRT14 marks a subpopulation of bladder basal cells with pivotal role in regeneration and tumorigenesis.

Papafotiou G, Paraskevopoulou V, Vasilaki E, Kanaki Z, Paschalidis N, Klinakis A.

Nat Commun. 2016 Jun 20;7:11914. doi: 10.1038/ncomms11914.

12.

Molecular substratification of bladder cancer: moving towards individualized patient management.

Mitra AP.

Ther Adv Urol. 2016 Jun;8(3):215-33. doi: 10.1177/1756287216638981. Epub 2016 Mar 28. Review.

13.

Androgen receptor expands the population of cancer stem cells in upper urinary tract urothelial cell carcinoma cells.

Chen CC, Hsieh TF, Huang CP, Yu AL, Chang WL, Shyr CR.

Am J Cancer Res. 2016 Jan 15;6(2):238-48. eCollection 2016.

14.
15.

Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis.

Liu Q, Yuan W, Tong D, Liu G, Lan W, Zhang D, Xiao H, Zhang Y, Huang Z, Yang J, Zhang J, Jiang J.

Oncotarget. 2016 May 10;7(19):28235-46. doi: 10.18632/oncotarget.8595.

16.

Cancer stem cells in prostate cancer.

Moltzahn F, Thalmann GN.

Transl Androl Urol. 2013 Sep;2(3):242-53. doi: 10.3978/j.issn.2223-4683.2013.09.06. Review.

17.

Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives.

Ohishi T, Koga F, Migita T.

Int J Mol Sci. 2015 Dec 29;17(1). pii: E43. doi: 10.3390/ijms17010043. Review.

18.

Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines.

Skowron MA, Niegisch G, Fritz G, Arent T, van Roermund JG, Romano A, Albers P, Schulz WA, Hoffmann MJ.

J Exp Clin Cancer Res. 2015 Nov 25;34:144. doi: 10.1186/s13046-015-0259-x.

19.

Altered expression of CKs 14/20 is an early event in a rat model of multistep bladder carcinogenesis.

Gil da Costa RM, Oliveira PA, Vasconcelos-Nóbrega C, Arantes-Rodrigues R, Pinto-Leite R, Colaço AA, de la Cruz LF, Lopes C.

Int J Exp Pathol. 2015 Oct;96(5):319-25. doi: 10.1111/iep.12145. Epub 2015 Oct 30.

20.

Update on The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer.

Lerner SP.

Eur Urol Focus. 2015 Aug;1(1):94-95. No abstract available.

Supplemental Content

Support Center